Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
Holding PEN?
Track your performance easily
PEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$148.00 - $277.34
Previous Close$187.06
Volume464.30K
Average Volume (3M)470.23K
Market Cap
$7.27B
Enterprise Value$7.16B
Total Cash (Recent Filing)$339.69M
Total Debt (Recent Filing)$228.82M
Price to Earnings (P/E)546.3
Beta0.97
Next Earnings
Oct 30, 2024EPS Estimate
$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding38,843,936
10 Day Avg. Volume432,704
30 Day Avg. Volume470,232
Standard Deviation0.14
R-Squared0.04
Alpha0.00819
Financial Highlights & Ratios
Price to Book (P/B)6.26
Price to Sales (P/S)6.43
Price to Cash Flow (P/CF)80.30
P/FCF Ratio98.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.31
Enterprise Value/Gross Profit10.48
Enterprise Value/Ebitda-151.08
Forecast
1Y Price Target
$202.31Price Target Upside3.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Penumbra News
PremiumThe Fly
Penumbra rises 12.2%Bulls Say, Bears Say
Bulls Say
Financial PerformancePEN's positive FCF profile and top-line growth place the company in 'more-rarified air' within the larger MedTech landscape, thereby lowering trading risk and justifying a higher multiple.
InnovationPEN's innovation engine, evidenced by continuous product launches, creates differentiation in an increasingly competitive space.
Market LeadershipPEN is the global leader of mechanical thrombectomy (MT), a procedure used to remove blood clots across various vascular diseases and disorders.
Bears Say
CompetitionIncreased competition from other NYC area hospitals as they establish and ramp their PE response team programs.
Market PerformanceLack of clear visibility on the current composition of revenue between the different commercial markets included in Penumbra's newly reported Thrombectomy segment has weighed on the stock.
Revenue GuidancePenumbra lowered its 2024 sales guidance from $1.23-$1.27B (up 16-20% yr/yr) to $1.18-$1.20B (up 11-13% yr/yr).
---
Ownership Overview
6.01% Insiders
48.12% Mutual Funds
44.87% Other Institutional Investors
1.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $148.00 and its highest was $277.34 in the past 12 months.
What is Penumbra’s market cap?
Currently, no data Available
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Oct 30, 2024 which is in 41 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Jul 30, 2024. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.556 by $0.084.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is $0.7.
How many shares outstanding does Penumbra have?
Penumbra has 38,843,937 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $0.64 in its last earnings report, beating expectations of $0.556. Following the earnings report the stock price went down -3.466%.
Which hedge fund is a major shareholder of Penumbra?
Among the largest hedge funds holding Penumbra’s share is PRIMECAP Management Co. It holds Penumbra’s shares valued at 7M.
---
Penumbra Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$202.31 (3.44% Upside)
$202.31 (3.44% Upside)
Blogger Sentiment
Bullish
PEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 6.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.09%
12-Months-Change
Fundamentals
Return on Equity
1.28%
Trailing 12-Months
Asset Growth
7.12%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
---
PEN Earnings Call
Q2 2024
0:00 / 0:00
---
PEN Stock 12 Month Forecast
Average Price Target
$202.31
▲(3.44% Upside)
Technical Analysis
Best Analysts Covering PEN
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+9.05%
assigned a buy rating 2 months ago
Copying David Rescott's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +9.05% per trade.
---